Pacira BioSciences (NASDAQ:PCRX) Receives “Sector Perform” Rating from Royal Bank of Canada

Royal Bank of Canada reiterated their sector perform rating on shares of Pacira BioSciences (NASDAQ:PCRX) in a research note published on Tuesday morning,Benzinga reports. Royal Bank of Canada currently has a $18.00 target price on the stock.

Several other research analysts have also recently issued reports on the stock. Jefferies Financial Group raised their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. HC Wainwright reissued a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a report on Wednesday, December 4th. Barclays lowered their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Finally, Needham & Company LLC raised their target price on Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Pacira BioSciences currently has a consensus rating of “Hold” and an average target price of $24.50.

Pacira BioSciences Trading Up 0.8 %

NASDAQ PCRX opened at $22.06 on Tuesday. The stock has a 50-day moving average of $18.60 and a 200-day moving average of $17.55. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $34.01. The firm has a market cap of $1.02 billion, a PE ratio of -10.87 and a beta of 0.76.

Institutional Investors Weigh In On Pacira BioSciences

Several hedge funds have recently made changes to their positions in the company. Pacer Advisors Inc. lifted its position in Pacira BioSciences by 129.4% during the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after buying an additional 2,799,434 shares during the period. Renaissance Technologies LLC lifted its position in Pacira BioSciences by 9.8% during the 2nd quarter. Renaissance Technologies LLC now owns 2,066,197 shares of the company’s stock valued at $59,114,000 after acquiring an additional 184,000 shares during the period. State Street Corp boosted its stake in Pacira BioSciences by 5.8% during the third quarter. State Street Corp now owns 2,014,012 shares of the company’s stock worth $30,311,000 after acquiring an additional 110,162 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Pacira BioSciences by 12.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock worth $52,300,000 after acquiring an additional 198,936 shares in the last quarter. Finally, Doma Perpetual Capital Management LLC grew its holdings in Pacira BioSciences by 71.8% in the second quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock worth $28,632,000 after purchasing an additional 418,321 shares during the period. 99.73% of the stock is currently owned by institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.